Literature DB >> 8706775

Omeprazole and lansoprazole are not inducers of cytochrome P4501A2 under conventional therapeutic conditions.

N Rizzo1, C Padoin, S Palombo, J M Scherrmann, C Girre.   

Abstract

OBJECTIVES: Claims that substituted benzimidazole molecules induce cytochromes P4501A2 are still controversial. This study was undertaken to evaluate their inducing potency under conventional therapeutic conditions.
METHODS: Twelve healthy non-smoking young volunteers were given 20 mg omeprazole or 30 mg lansoprazole daily, in random order, for 2 weeks, separated by a 3 week wash-out period. We evaluated the CYP1A2 activity by the ratio of the molar urinary concentrations (CUM ratio) of the three end products of the paraxanthine demethylation of caffeine over the molar concentration of a paraxanthine 8-hydroxylation product.
RESULTS: This urinary metabolite ratio has previously been shown to be correlated with caffeine clearance. There was slight but non-significant enhancement of the CUM ratio after 2 weeks of treatment with omeprazole (3.62 (1.58) on Day 15 vs 3.09 (1.43) on Day 1), and after lansoprazole (4.26 (2.3) vs 3.65 (2.36)). Similarly, one week of treatment did not significantly alter the CUM ratio after omeprazole or lansoprazole (3.11 (1.58) and 3.28 (1.59), respectively on Day 8).
CONCLUSION: The results show that both omeprazole and lansoprazole in the daily recommended therapeutic doses of 20 mg and 30 mg, respectively, have no influence on the metabolism of caffeine, and therefore no influence on cytochrome CYP1A2 activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8706775     DOI: 10.1007/BF00195936

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  25 in total

1.  Cytochrome P450 IA2 activity in man measured by caffeine metabolism: effect of smoking, broccoli and exercise.

Authors:  K Vistisen; S Loft; H E Poulsen
Journal:  Adv Exp Med Biol       Date:  1991       Impact factor: 2.622

2.  No influence of single intravenous doses of omeprazole on theophylline elimination kinetics.

Authors:  B Oosterhuis; J H Jonkman; T Andersson; P B Zuiderwijk
Journal:  J Clin Pharmacol       Date:  1992-05       Impact factor: 3.126

3.  A population and family study of CYP1A2 using caffeine urinary metabolites.

Authors:  A Catteau; Y C Bechtel; N Poisson; P R Bechtel; C Bonaïti-Pellie
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

4.  Variability in caffeine metabolism.

Authors:  D M Grant; B K Tang; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1983-05       Impact factor: 6.875

5.  Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450.

Authors:  D Diaz; I Fabre; M Daujat; B Saint Aubert; P Bories; H Michel; P Maurel
Journal:  Gastroenterology       Date:  1990-09       Impact factor: 22.682

6.  A urinary metabolite ratio that reflects systemic caffeine clearance.

Authors:  M E Campbell; S P Spielberg; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1987-08       Impact factor: 6.875

7.  Omeprazole treatment does not affect the metabolism of caffeine.

Authors:  T Andersson; R Bergstrand; C Cederberg; S Eriksson; P O Lagerström; I Skånberg
Journal:  Gastroenterology       Date:  1991-10       Impact factor: 22.682

8.  Enhanced phenacetin metabolism in human subjects fed charcoal-broiled beef.

Authors:  A H Conney; E J Pantuck; K C Hsiao; W A Garland; K E Anderson; A P Alvares; A Kappas
Journal:  Clin Pharmacol Ther       Date:  1976-12       Impact factor: 6.875

9.  Characterisation of theophylline metabolism by human liver microsomes. Inhibition and immunochemical studies.

Authors:  R A Robson; J O Miners; A P Matthews; I Stupans; D Meller; M E McManus; D J Birkett
Journal:  Biochem Pharmacol       Date:  1988-05-01       Impact factor: 5.858

10.  Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man.

Authors:  D Sesardic; A R Boobis; B P Murray; S Murray; J Segura; R de la Torre; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

View more
  9 in total

Review 1.  Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.

Authors:  H D Langtry; M I Wilde
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

Review 2.  [Drug interactions. Mechanisms and clinical relevance].

Authors:  U Klotz; W Beil; C Gleiter; B Drewelow; E Garbe; A Gillessen; E Mutschler
Journal:  Internist (Berl)       Date:  2003-11       Impact factor: 0.743

3.  Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole.

Authors:  T Andersson; J Holmberg; K Röhss; A Walan
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

Review 4.  Pharmacokinetic considerations in the eradication of Helicobacter pylori.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 5.  Clinically significant pharmacokinetic interactions between dietary caffeine and medications.

Authors:  J A Carrillo; J Benitez
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

Review 6.  Drug-drug interaction profiles of proton pump inhibitors.

Authors:  Ryuichi Ogawa; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2010-08       Impact factor: 6.447

7.  Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline.

Authors:  K Dilger; Z Zheng; U Klotz
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

Review 8.  Rational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: drug metabolism and its related interactions.

Authors:  Quan Zhou; Xiao-Feng Yan; Zhong-Miao Zhang; Wen-Sheng Pan; Su Zeng
Journal:  World J Gastroenterol       Date:  2007-11-14       Impact factor: 5.742

Review 9.  Drug-Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes.

Authors:  Florian Klomp; Christoph Wenzel; Marek Drozdzik; Stefan Oswald
Journal:  Pharmaceutics       Date:  2020-12-11       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.